Skip to main content
. 2019 Aug 27;8:144. doi: 10.1186/s13756-019-0599-y

Fig. 2.

Fig. 2

Kaplan-Meier 28 day survival estimates among ESBL-producing E. coli BSI patients depending on treatment with carbapenem or β-lactam-β-lactamase inhibitor (BLBLI) combination antibiotics